Brainstorm Cell Therapeutics Gains Pre-Bell

Brainstorm Cell Therapeutics shares were higher 18% in recent pre-market trade after the company said data from a phase 2 study of NurOwn in amyotrophic lateral sclerosis, or Lou Gehrig’s disease, suggest “strong biological effect” and evidence of halting disease progression.

The company said there was a statistically significant increase in levels of neurotrophic factors VEGF, HGF and LIF from pre- to post-transplantation as well as a significant reduction in inflammatory markers in patients treated with NurOwn and this was not observed in the placebo group.

It said that in the NurOwn treated group, a greater number of patients achieved the high threshold of 100% improvement in the post-treatment vs. pre-treatment slope, compared with the placebo group.

Leave a Comment